Kailera Therapeutics’ planned IPO will fund ongoing clinical development of a pipeline led by a drug that could rival Eli Lilly’s Zepbound in both efficacy and tolerability. Meanwhile, Renaissance Capital’s recap of first quarter 2026 IPOs shows slowing activity amid market turbulence from tariffs and war.
Bain Capital Private Equity led Kailera Therapeutics’ Series B financing, which will support global Phase 3 tests of KAI-9531, a weekly injectable drug that hits the same targets as Eli Lilly’s blockbuster obesity medication, Zepbound. The capital will also support development of other oral and injectable metabolic medicines in Kailera’s pipeline.
Healthcare payments are no longer about transactions. It’s about controlling the revenue cycle. And increasingly, that control is not sitting with ISOs.
Obesity and type 2 diabetes are among the cardiometabolic diseases included in Novo Nordisk’s R&D pact with Replicate Bioscience, a deal that could pay out up to $550 million. Startup Replicate specializes in therapies and vaccines based on self-replicating RNA.
The first Phase 3 results for Eli Lilly’s daily pill orforglipron show statistically significant reductions in blood sugar and body weight in patients with type 2 diabetes. The pharmaceutical giant plans global regulatory submissions starting at the end of this year.
Novo Nordisk is licensing rights to a United Biotechnology drug that sparks metabolic effects by binding to and activating receptors for GLP-1, GIP, and glucagon. Separately, the pharma giant said its recently announced discounted price for obesity medication Wegovy is now expanding to traditional pharmacies.
CagriSema, a dual-acting drug in development by Novo Nordisk, met the goal of a Phase 3 test in patients with obesity and type 2 diabetes. But the topline results don’t show an advantage over Eli Lilly’s commercialized obesity medication, Zepbound.
We'll explore why the next era of payer performance will depend on building a trusted data foundation that connects people, providers, and relationships across the enterprise.
Novo Nordisk’s type 2 diabetes drug Ozempic has expanded its label to include chronic kidney disease. The new FDA approval comes as makers of GLP-1 drugs work to expand the uses of these products.
Novo Nordisk and Valo Health have collaborated on the development of cardiovascular disease drugs since 2023. Expanding the alliance to cardiometabolic diseases nearly doubles the number of programs covered under the agreement.
Effective diabetes management requires a shift from focusing purely on blood sugar levels and weight management medications to embracing the psychological and biological contributors that drive obesity and the disease.
Positive preliminary results for Eli Lilly’s efsitora alfa continue to build the case for this once-weekly insulin in type 2 diabetes patients. Lilly is trying to catch up to Novo Nordisk’s once weekly insulin icodec, which is commercially available in several markets around the world but is not yet approved by the FDA.
In an interview, Kyan Health Co-Founder and Chief Commercial Officer Konstantin Struck discussed how Kyan gives mid-market and enterprise employers access to premium workforce mental healthcare, at a price point that is affordable.
In a Phase 3 study, Eli Lilly’s tirzepatide led to a 94% reduction in the risk that obese or overweight prediabetes patients progress to type 2 diabetes. Lilly was already planning to expand use of the blockbuster metabolic disorders drug to sleep apnea and heart failure.
Roche reported its oral GLP-1 agonist led to an average 6.1% weight loss at four weeks, according to preliminary results from part of a Phase 1 study. The small molecule comes from Roche’s $2.7 billion acquisition of Carmot Therapeutics last year.
Eli Lilly says its capital commitment to its new Indiana site is the largest manufacturing investment in the company’s history. The site will make tirzepatide, the active pharmaceutical ingredient in both Zepbound and Mounjaro.
Virta is available this month to all Blue Shield of California members enrolled in preferred provider organization plans for individual and family, fully insured, self funded and Medicare Advantage. The payer has been working with Virta since 2019 when the digital health company joined Blue Shield of California’s Wellvolution, a platform of digital lifestyle apps.
Medicare Advantage patients with diabetes have higher prescription fill rates, fewer emergency department visits and lower total medical spending than traditional fee-for-service Medicare patients, a new report shows. They also received their diagnosis earlier.